Loading clinical trials...
Loading clinical trials...
Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up
Conditions
Interventions
Cervarix
Locations
6
Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Würzburg, Bavaria, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Bydgoszcz, Poland
GSK Investigational Site
Poznan, Poland
GSK Investigational Site
Poznan, Poland
Start Date
October 7, 2004
Primary Completion Date
December 15, 2005
Completion Date
December 15, 2005
Last Updated
December 11, 2019
NCT01627561
NCT01462357
NCT01190176
NCT01277042
NCT00345878
NCT00426361
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions